Hikma Pharmaceuticals Plc (HIK) Downgraded by JPMorgan Chase & Co.

JPMorgan Chase & Co. lowered shares of Hikma Pharmaceuticals Plc (LON:HIK) to a neutral rating in a research note issued to investors on Thursday. JPMorgan Chase & Co. currently has GBX 2,400 ($29.64) target price on the stock, up from their prior target price of GBX 2,100 ($25.94).

A number of other brokerages have also recently commented on HIK. Peel Hunt reissued a buy rating and issued a GBX 2,340 ($28.90) price target on shares of Hikma Pharmaceuticals Plc in a research report on Wednesday, March 15th. Numis Securities Ltd cut Hikma Pharmaceuticals Plc to an add rating and set a GBX 2,350 ($29.02) price target on the stock. in a research report on Friday, March 10th. Jefferies Group LLC boosted their price target on Hikma Pharmaceuticals Plc from GBX 2,065 ($25.50) to GBX 2,162 ($26.70) and gave the stock a buy rating in a research report on Tuesday, January 17th. Citigroup Inc reissued a neutral rating on shares of Hikma Pharmaceuticals Plc in a research report on Wednesday, November 16th. Finally, AlphaValue reissued a buy rating and issued a GBX 2,431 ($30.02) price target on shares of Hikma Pharmaceuticals Plc in a research report on Wednesday, November 30th. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating and six have given a buy rating to the company. The company currently has a consensus rating of Buy and an average target price of GBX 2,353.67 ($29.07).

Hikma Pharmaceuticals Plc (LON:HIK) opened at 2121.44 on Thursday. Hikma Pharmaceuticals Plc has a 12-month low of GBX 1,575.00 and a 12-month high of GBX 2,703.00. The stock’s market capitalization is GBX 4.79 billion. The firm’s 50-day moving average is GBX 2,047.69 and its 200 day moving average is GBX 1,925.38.

Your IP Address:

The firm also recently disclosed a dividend, which will be paid on Thursday, May 25th. Investors of record on Thursday, April 6th will be given a GBX 0.22 ($0.00) dividend. The ex-dividend date of this dividend is Thursday, April 6th. This is a boost from Hikma Pharmaceuticals Plc’s previous dividend of $0.21. This represents a yield of 0.78%.

Hikma Pharmaceuticals Plc Company Profile

Hikma Pharmaceuticals Plc is a pharmaceutical company. The Company develops, manufactures and markets a range of branded and non-branded generic pharmaceutical products in solid, semi-solid, liquid and injectable final dosage forms, across the United States, the Middle East and North Africa (MENA) region and Europe.

Receive News & Ratings for Hikma Pharmaceuticals Plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hikma Pharmaceuticals Plc and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply